Large pregnancy study finds different preterm-birth risks for Ozempic and Wegovy depending on the reason for use
What the study found
Researchers analyzing more than 750,000 pregnancies examined early exposure to Ozempic, Wegovy, and similar drugs. When the medicines were prescribed for weight loss, their use was not associated with an increased risk of pregnancy complications.
The result differed when the same drugs were prescribed for diabetes. In those cases, exposure was associated with a higher risk of premature birth.
Why the reason for use matters
The contrast suggests that diabetes itself may contribute to the elevated premature-birth risk rather than the medications alone. In other words, simply combining outcomes for people taking the drugs for weight loss and those taking them for diabetes could obscure important differences between the groups.
The findings do not establish that the drugs are safe during pregnancy. Researchers cautioned that safety remains uncertain, and an association with premature birth in the diabetes group does not identify the precise cause.
The takeaway
The study points to a need to consider why a drug was prescribed when assessing pregnancy outcomes. It offers no clear increase in complications from early weight-loss use, but the elevated premature-birth signal among pregnancies involving diabetes leaves an important question unresolved. More research will be needed to separate the effects of treatment from those of the underlying condition.